tiprankstipranks
Abbvie (GB:0QCV)
NYSE:0QCV
UK Market
0QCV
AbbVie
RESEARCH TOOLSreports

AbbVie (0QCV) Share Forecast & Price Target

12 Followers
See the Price Targets and Ratings of:

0QCV Analyst Ratings

Strong Buy
20Ratings
Strong Buy
16 Buy
4 Hold
0 Sell
Based on 20 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QCV Stock 12 Month Forecast

Average Price Target

$256.47
▲(22.22% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $256.47 with a high forecast of $298.00 and a low forecast of $203.00. The average price target represents a 22.22% change from the last price of $209.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"179":"$179","209":"$209","239":"$239","269":"$269","299":"$299"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":298,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$298.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":256.47058823529414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$256.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$203.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[179,209,239,269,299],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.36,219.87076923076924,226.38153846153847,232.8923076923077,239.40307692307692,245.91384615384615,252.42461538461538,258.93538461538463,265.44615384615383,271.9569230769231,278.4676923076923,284.97846153846154,291.48923076923074,{"y":298,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.36,216.67619909502264,219.99239819004526,223.3085972850679,226.62479638009052,229.94099547511314,233.25719457013577,236.5733936651584,239.88959276018102,243.20579185520364,246.52199095022627,249.8381900452489,253.15438914027152,{"y":256.47058823529414,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.36,212.56307692307695,211.76615384615386,210.9692307692308,210.1723076923077,209.37538461538463,208.57846153846154,207.78153846153847,206.98461538461538,206.18769230769232,205.39076923076922,204.59384615384616,203.79692307692306,{"y":203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":180.312,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.062,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.198,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":236.999,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.137,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.115,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.392,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.126,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.197,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.764,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$298.00Average Price Target$256.47Lowest Price Target$203.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on GB:0QCV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
23.90%
Upside
Reiterated
06/05/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), GMR Solutions, Inc. Class A (NYSE: GMRS) and Cullinan Management (NASDAQ: CGEM)
Bank of America Securities Analyst forecast on GB:0QCV
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/03/26
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)
Piper Sandler Analyst forecast on GB:0QCV
David Amsellem
Piper Sandler
Piper Sandler
$298
Buy
42.01%
Upside
Reiterated
06/02/26
Piper Sandler Reaffirms Their Buy Rating on AbbVie (ABBV)
Bernstein Analyst forecast on GB:0QCV
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), AbbVie (NYSE: ABBV) and Replimune Group (NASDAQ: REPL)
Morgan Stanley Analyst forecast on GB:0QCV
Terence Flynn
Morgan Stanley
Morgan Stanley
$278
Buy
32.48%
Upside
Reiterated
05/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (NASDAQ: KRYS), AbbVie (NYSE: ABBV) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Barclays Analyst forecast on GB:0QCV
Emily Field
Barclays
Barclays
$275
Buy
31.05%
Upside
Reiterated
05/29/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Healthequity (HQY)
Evercore ISI Analyst forecast on GB:0QCV
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$236→$235
Buy
11.99%
Upside
Assigned
05/15/26
AbbVie price target lowered to $235 from $236 at Evercore ISIAbbVie price target lowered to $235 from $236 at Evercore ISI
Argus Research Analyst forecast on GB:0QCV
Jasper Hellweg
Argus Research
Argus Research
$250
Buy
19.14%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
Berenberg Bank Analyst forecast on GB:0QCV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
31.05%
Upside
Reiterated
05/08/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
BMO Capital Analyst forecast on GB:0QCV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
22.95%
Upside
Reiterated
05/04/26
BMO Capital Sticks to Their Buy Rating for AbbVie (ABBV)
Citi Analyst forecast on GB:0QCV
Geoff Meacham
Citi
Citi
$230
Hold
9.61%
Upside
Reiterated
05/01/26
Citi Keeps Their Hold Rating on AbbVie (ABBV)
Guggenheim Analyst forecast on GB:0QCV
Vamil Divan
Guggenheim
Guggenheim
$249
Buy
18.66%
Upside
Reiterated
04/30/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Scotiabank Analyst forecast on GB:0QCV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
33.43%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), AxoGen (NASDAQ: AXGN) and Niagen Bioscience (NASDAQ: NAGE)
Canaccord Genuity Analyst forecast on GB:0QCV
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$262→$265
Buy
26.29%
Upside
Reiterated
04/30/26
Canaccord Genuity Sticks to Their Buy Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on GB:0QCV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
23.90%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), AbbVie (NYSE: ABBV) and Humana (NYSE: HUM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on GB:0QCV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
23.90%
Upside
Reiterated
06/05/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), GMR Solutions, Inc. Class A (NYSE: GMRS) and Cullinan Management (NASDAQ: CGEM)
Bank of America Securities Analyst forecast on GB:0QCV
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/03/26
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)
Piper Sandler Analyst forecast on GB:0QCV
David Amsellem
Piper Sandler
Piper Sandler
$298
Buy
42.01%
Upside
Reiterated
06/02/26
Piper Sandler Reaffirms Their Buy Rating on AbbVie (ABBV)
Bernstein Analyst forecast on GB:0QCV
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), AbbVie (NYSE: ABBV) and Replimune Group (NASDAQ: REPL)
Morgan Stanley Analyst forecast on GB:0QCV
Terence Flynn
Morgan Stanley
Morgan Stanley
$278
Buy
32.48%
Upside
Reiterated
05/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (NASDAQ: KRYS), AbbVie (NYSE: ABBV) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Barclays Analyst forecast on GB:0QCV
Emily Field
Barclays
Barclays
$275
Buy
31.05%
Upside
Reiterated
05/29/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Healthequity (HQY)
Evercore ISI Analyst forecast on GB:0QCV
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$236→$235
Buy
11.99%
Upside
Assigned
05/15/26
AbbVie price target lowered to $235 from $236 at Evercore ISIAbbVie price target lowered to $235 from $236 at Evercore ISI
Argus Research Analyst forecast on GB:0QCV
Jasper Hellweg
Argus Research
Argus Research
$250
Buy
19.14%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
Berenberg Bank Analyst forecast on GB:0QCV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
31.05%
Upside
Reiterated
05/08/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
BMO Capital Analyst forecast on GB:0QCV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
22.95%
Upside
Reiterated
05/04/26
BMO Capital Sticks to Their Buy Rating for AbbVie (ABBV)
Citi Analyst forecast on GB:0QCV
Geoff Meacham
Citi
Citi
$230
Hold
9.61%
Upside
Reiterated
05/01/26
Citi Keeps Their Hold Rating on AbbVie (ABBV)
Guggenheim Analyst forecast on GB:0QCV
Vamil Divan
Guggenheim
Guggenheim
$249
Buy
18.66%
Upside
Reiterated
04/30/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Scotiabank Analyst forecast on GB:0QCV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
33.43%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), AxoGen (NASDAQ: AXGN) and Niagen Bioscience (NASDAQ: NAGE)
Canaccord Genuity Analyst forecast on GB:0QCV
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$262→$265
Buy
26.29%
Upside
Reiterated
04/30/26
Canaccord Genuity Sticks to Their Buy Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on GB:0QCV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
23.90%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), AbbVie (NYSE: ABBV) and Humana (NYSE: HUM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
Chris SchottJ.P. Morgan
Success Rate
22/30 ratings generated profit
73%
Average Return
+7.45%
Copying Chris Schott's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +7.45% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
28/28 ratings generated profit
100%
Average Return
+18.37%
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.37% per trade.
2 Years
Gary NachmanCanaccord Genuity
Success Rate
29/29 ratings generated profit
100%
Average Return
+33.34%
Copying Gary Nachman's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QCV Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
28
30
45
45
37
Hold
14
14
11
8
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
44
56
53
44
In the current month, 0QCV has received 37 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0QCV average Analyst price target in the past 3 months is 256.47.
Each month's total comprises the sum of three months' worth of ratings.

0QCV Financial Forecast

0QCV Earnings Forecast

Next quarter’s earnings estimate for 0QCV is $3.76 with a range of $3.70 to $3.93. The previous quarter’s EPS was $2.65. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0QCV is $3.76 with a range of $3.70 to $3.93. The previous quarter’s EPS was $2.65. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.

0QCV Sales Forecast

Next quarter’s sales forecast for 0QCV is $16.78B with a range of $16.56B to $16.93B. The previous quarter’s sales results were $15.00B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.
Next quarter’s sales forecast for 0QCV is $16.78B with a range of $16.56B to $16.93B. The previous quarter’s sales results were $15.00B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0QCV has Performed in-line its overall industry.

0QCV Stock Forecast FAQ

What is GB:0QCV’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 256.47.
    What is GB:0QCV’s upside potential, based on the analysts’ average price target?
    Abbvie has 22.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbvie a Buy, Sell or Hold?
          Abbvie has a consensus rating of Strong Buy, which is based on 16 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Abbvie’s share price target?
            The average share price target for Abbvie is 256.47. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $298.00 ,and the lowest forecast is $203.00. The average share price target represents 22.22% Increase from the current price of $209.84.
              What do analysts say about Abbvie?
              Abbvie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Abbvie?
                To buy shares of GB:0QCV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.